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ABSTRACT 
 
The imprinted expression of the IGF2 and H19 genes is controlled by the 
imprinting control region 1 (ICR1) located at chromosome 11p15.5. This 
methylation-sensitive chromatin insulator works by binding the zinc-finger 
protein CTCF in a parent-specific manner. CTCF binds the unmethylated 
maternal allele and is required for preventing de novo methylation at ICR1. 
 
DNA methylation defects involving the ICR1 IGF2/H19 domain result in two 
growth disorders with opposite phenotypes: an overgrowth disorder, the 
Beckwith-Wiedemann syndrome (ICR1 gain of methylation in 10% of BWS 
cases) and a growth retardation disorder, the Silver-Russell syndrome (ICR1 
loss of methylation in 60% of SRS cases). Little information is available 
regarding the mechanism of ICR1 DNA methylation defects. Several deletions 
removing part of ICR1 (1.4 to 2.2 kb) have been described in a few familial 
BWS cases with dominant maternal transmission. 
 
In order to evaluate precisely the incidence of ICR1 mutations, we 
investigated, by long range PCR and sequencing, 21 BWS patients (including 
two brothers) with ICR1 gain of methylation and 16 SRS patients with ICR1 
loss of methylation. 
 
No mutation of the seven CTCF binding sites was detected in the familial BWS 
cases. Two additional cases of constitutional genetic lesions were identified in 
BWS patients with apparently-sporadic forms. One patient was identified with 
a 8 bp deletion within the B3 repeat, 116 bases 3’ of the CTCF binding site 4. 
Another patient was identified with a 1.8 kb deletion which eliminates CTCF 
binding sites 2 and 3. A single-nucleotide variation was identified in a SRS 
patient.  
 
Our data showed that ICR1 deletions, including new small deletions, account 
for apparently sporadic forms of BWS with ICR1 gain of methylation. ICR1 
deletions are associated with a high incidence of Wilms’ tumour, making their 
molecular diagnosis particularly important for genetic counseling and tumor 
surveillance. 
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2 
1 INTRODUCTION  
 
1.1 Genomic Imprinting 
 
The majority of genes in diploid organisms are expressed from both 
alleles. However, a number of genes are expressed from one of the two 
parental alleles; these genes are known as imprinted genes. In the 
same cell, some imprinted genes are expressed from paternally 
inherited alleles (maternally imprinted) and others are expressed from 
maternally inherited alleles (paternally imprinted) (SOLTER 2006). 
 
In the early 1980s, two different pronucleus transplantation studies 
demonstrated that the paternal and maternal chromosomes do not 
have equivalent functions and that both genomes are essentially 
required for normal mammalian development (MCGRATH and SOLTER 
1984; SURANI et al. 1984). One decade later, the maternally expressed 
Igf2r gene (Insulin-like growth factor-2 receptor) was the first gene 
found to be expressed in a parent of origin-dependent manner and 
defined as an imprinted gene (BARLOW et al. 1991). The same year, two 
other imprinted genes, the Igf2 and H19 genes on the mouse 
chromosome 7 were shown to display reciprocal imprinting and to be 
paternally and maternally expressed respectively (BARTOLOMEI et al. 
1991; DECHIARA et al. 1991). Many other imprinted genes have since 
been discovered and more than 80 imprinted genes have been 
reported in mammals so far (http://www.geneimprint.com).  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
Genomic imprinting is highly conserved among mice, ruminants and 
humans (DELAVAL and FEIL 2004). A conflicting theory of genomic 
imprinting suggests that imprinting arose because of a genomic tug-of-
war between the two parents where maternally expressed genes inhibit 
growth while paternally expressed genes promote growth (WEIDMAN 
2007) . Imprinted genes often code for proteins involved in foetal 
growth and development and placental function (GICQUEL et al. 2008). 
Other imprinted genes are also expressed in the brain and influence 
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the developmental processes of the brain as well as brain function and 
behaviour (WILKINSON et al. 2007). Therefore, any disturbance of 
genomic imprinting results in many growth and mental disorders and 
learning disability (GICQUEL et al. 2008; WILKINSON et al. 2007).  
 
1.1.1 Characteristics of imprinted genes  
 
Imprinted genes display common features. Almost all known imprinted 
genes are organized in clusters which usually include both imprinted 
and nonimprinted genes (WEIDMAN 2007). Clusters of imprinted genes 
are regulated by single major cis-acting elements which are known as 
imprinting control regions (ICRs). These regions are CpG (Cytosine-
phosphate-Guanine) rich regions up to several kilobases in length and 
are differentially methylated between the two parental alleles 
(differentially methylated regions (DMRs)) (LEWIS and REIK 2006). 
ICRs are also marked by histone modifications (phosphorylation, 
methylation, acetylation and ubiquitinylation) (KOUZARIDES 2007). As a 
result, ICRs are essential for the regulation of the expression of 
imprinted genes in an allele-specific manner. 
 
ICRs regulate imprinted gene expression by two main mechanisms; 
chromatin insulator and non-coding RNA gene (ncRNA) (SHA 2008; 
WEIDMAN 2007) (i) Chromatin insulator mediates imprinted gene 
expression through special DNA sequences at ICRs. These sequences 
bind specific proteins, such as the CTCF protein (see 1.2.4.2), which 
prevents the interaction between gene promoters and enhancers and 
therefore suppresses gene expression (LEWIS and REIK 2006). (ii) 
Another mechanism of regulation of imprinted gene expression involves 
ncRNA genes. Each imprinted cluster expresses at least one large 
ncRNA that displays reciprocal imprinted expression relative to the 
neighbouring coding genes. Some of these ncRNA genes are 
transcribed in an antisense orientation relative to the protein-coding 
genes. These long ncRNA genes act as cis-acting silencers. Imprinted 
gene clusters also contain small regulatory ncRNAs, and particularly 
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microRNAs which act as trans-acting regulators (ROYO and CAVAILLE 
2008). 
 
Another feature associated with imprinted genes is a difference in the 
timing of allele replication between the two parental alleles. The 
replication timing pattern has been examined for some imprinted genes 
in the mouse and it has been shown that the paternal allele replicates 
earlier than the maternal allele (SHA 2008). 
 
1.1.2 Epigenetic marks of imprinted genes 
 
Homologous genes, which carry the same genetic information, can be 
expressed differentially according to the parental origin. In imprinted 
genes, the maternal and paternal alleles convey different gene 
expression as a result of different epigenetic marks without affecting 
the genetic code (TRASLER 2006). Therefore, the epigenetic marks tell 
the cell which parental copy of imprinted genes must be activated. DNA 
methylation and histone modifications are the two common epigenetic 
marks which are involved in imprinted gene regulation. 
 
1.1.2.1 DNA methylation 
 
DNA methylation is one aspect of epigenetic modifications in which the 
5‟ position of cytosine in the CpG dinucleotide acquires a methyl group 
(SHA 2008). This epigenetic mark is inherited throughout replication and 
is essential for the mammalian development (LI 2002; OKANO et al. 
1999). Regarding imprinted genes, the DNA methylation pattern 
undergoes a cycle which is discussed in section (1.2.3). 
 
Addition and maintenance of a methyl group at the 5‟ position of 
cytosine within CpG dinucleotides are mediated by DNA 
methyltransferases (Dnmts) (table I). Dnmts which introduce a methyl 
group at previously unmethylated CpG sites are known as de novo 
methyltransferases (Dnmt3 family) (TRASLER 2006). Dnmt3a and 
Dnmt3b are essential for de novo methylation in early postimplantation 
embryos but they have no effect on maintenance of imprinted 
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methylation patterns (BESTOR 2000; HATA et al. 2002). Dnmt3l is a 
protein sharing homology with Dnmt3 a and b to carry out de novo 
methylation of maternally imprinted genes in oocytes (BOURC'HIS et al. 
2001; HATA et al. 2002). 
 
The other Dnmts group is involved in the maintenance of the pre-
existing methylation, this group is known as maintenance 
methyltransferases (Dnmt1 group). Dnmt1 copies the pre-existing 
methylation pattern during DNA replication into the new DNA strand 
(HOWELL et al. 2001; LI et al. 1992). Dnmt1o is an oocyte isoform of 
Dnmt1 and is crucial for the maintenance of DNA methylation at 
imprinted loci in the fourth S phase of embryogenesis (HOWELL et al. 
2001). Following the implantation, the oocyte specific Dnmt1o 
disappears and Dnmt1 protein maintains the methylation during 
development (HOWELL et al. 2001; LI et al. 1992; TRASLER et al. 1996). 
 
Normal DNA methylation status is required for controlling differential 
expression of the paternal and maternal alleles of imprinted genes. 
Aberrant DNA methylation is linked to a number of imprinting-related 
disorders in humans (GICQUEL et al. 2008; GICQUEL et al. 2005; 
TRASLER 2006). The mechanistic role of DNA methylation in association 
with gene expression remains largely unclear. In imprinted regions, 
spreading of DNA methylation along ICRs is suggested to coordinate 
gene expression of a cluster (SHA 2008; TURKER 1999). Recently, long-
range chromatin interaction or “looping”, which is modulated by both 
DNA methylation and histone modifications, has been proposed for 
coordination of imprinted gene expression (LOPES et al. 2003; MURRELL 
et al. 2004).  
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Table I:  Role of the different DNA methyltransferases 
DNA 
methyltransferase 
Function 
Specific role in 
genomic imprinting 
References 
    
Dnmt1 Maintenance of the 
pre-existing methyl 
pattern during DNA 
replication. 
Dnmt1o isoform is 
required for 
maintenance of 
methylation at 
paternally and 
maternally imprinted 
loci during the fourth 
embryonic S phase. 
(LI et al. 
1992)  
(HOWELL et 
al. 2001)  
    
Dnmt3a De novo methylation 
during the embryonic 
developmental 
process. 
Methylation of 
maternal ICRs in 
association with 
Dnmt3l. 
(BESTOR 
2000) 
(HATA et al. 
2002) 
Redundancy with 
Dnmt3b.  
    
Dnmt3b De novo methylation 
during the embryonic 
developmental 
process. 
 (BESTOR 
2000) 
Redundancy with 
Dnmt3a. 
Specifically required 
for methylation of 
pericentromeric 
satellite repeats. 
    
Dnmt3l Absence of proper 
DNA 
methyltransferase 
activity. 
Methylation of 
maternal ICRs in 
association with 
Dnmt3a. 
(BOURC'HIS et 
al. 2001) 
 
 
1.1.2.2 Histone modifications and chromatin structure  
 
The other epigenetic marks involved in regulation of genomic imprinting 
are histone modifications. DMRs at imprinted loci are not only marked 
by DNA methylation but also by chromatin modifications that participate 
to a different chromatin organization between the parental alleles (SHA 
2008) (Fig. 1).  DNA wraps around a histone protein octamer which 
consists of two copies of each histone, H2A, H2B, H3 and H4 to form 
the nucleosome. Each histone contains a functional domain (N-terminal 
tail) that protrudes from the nucleosome and acts as a target site for 
enzymes and proteins (WORKMAN and KINGSTON 1998). N-terminal tails 
of histones can be modified by different post-translational modification 
mechanisms such as methylation, acetylation, phosphorylation and 
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ubiquitinylation. These mechanisms are catalysed by different enzymes 
(KOUZARIDES 2007). Histone modifications have different effects on the 
chromatin structure (BERGER 2007). Histone methylation is associated 
with active or inactive chromatin depending on the site of methylation. 
For example, addition of a methyl group, by histone methyl 
transferases (HMTs), to the histone 3 lysine 4 (H3K4) is associated 
with uncondensed (active) chromatin. On the other hand, H3K9 and 
H3K27 methylation are associated with condensed (inactive) 
chromatin. Lysine residues can be mono-, di- and trimethylated and 
provide further functional diversity to each methylated lysine residue 
(BERGER 2007; KOUZARIDES 2007; STRAHL and ALLIS 2000). Acetylation 
marks seem to be less complicated than methylation marks and 
commonly link to an active state at a given region due to a relaxed 
chromatin structure and increased access of transcriptional factors. For 
instance, H3 and H4 acetylation, mediated by histone acetyl 
transferases (HATs), are associated with transcriptional activation (LI et 
al. 2007).  
 
Although histone modifications are found independent of DNA 
methylation, there is clear evidence that links DNA methylation and 
histone modification to control gene expression (LEWIS et al. 2004). In 
different studies, DNA methylation was found to control histone 
modifications and vice versa. For example, DNA methylation recruits 
methylated CpG binding complexes that contain enzymes able to add a 
repressive methylation mark (H3K9) to histones (SARRAF and 
STANCHEVA 2004).  
 
The histone code of the murine ICR1 has been extensively 
characterized by Han et al. Rather than, displaying active histone 
modifications on the unmethylated allele and repressive histone 
modifications on the methylated allele, the allelic distribution of the 
histone marks vary along the ICR1 domain. Active marks (H3K4 
dimethylation, H3K4 trimethylation, H3K9 acetylation) are associated 
with the maternal H19 gene and the paternal IGF2 gene and the allelic 
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distribution is the opposite for repressive marks (H3K9 dimethylation, 
H3K27 trimethylation). Regarding the imprinting center itself, repressive 
marks are equally distributed on both parental alleles. Interestingly, 
deletion abolishing CTCF binding sites within ICR1 on the maternal 
allele results in the “paternalization of the maternal allele”(HAN et al. 
2008).  
 
  
Figure 1: Epigenetic marks and chromatin structure at DMRs. a) Active 
epigenetic marks on an active allele. Unmethylated DMR and active 
histone modifications (green circles) open the chromatin and allow the 
access of transcriptional factors to start transcription. b) Inactive 
epigenetic marks on an inactive allele. Methylated DNA (orange stars) 
and inactive histone modifications (beige circles) condense the 
chromatin and deny the access of transcriptional factors to start 
transcription (adapted from (OZANNE and CONSTANCIA 2007)). 
 
 
1.1.3 The imprinting cycle  
The epigenetic marks of imprinted genes change in characteristic ways 
during the life cycle of the organism. Three different stages are involved 
in the imprinting cycle: erasure of imprints, establishment of new 
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parent-specific imprints and maintenance of imprints throughout 
development (Fig. 2 and 3) (SOLTER 2006; TRASLER 2006).    
Erasure occurs in primordial germ cells in the gonads before their 
differentiation. All pre-existing imprints are erased during genome-wide 
demethylation in germ cells (HAJKOVA et al. 2002; LI 2002; SHA 2008; 
TADA et al. 1998). For example, the methylation of ICR1 at the 
IGF2/H19–ICR1 locus is erased in foetal spermatogonias and 
reappears later during spermatogonial differentiation in the adult testis 
(KERJEAN et al. 2000). Erasure of imprints is thought to be active but the 
enzymes involved in this developmental process are still unknown 
(TRASLER 2006).  
 
After erasure of previous imprints, de novo methylation begins in the 
male and female germ lines and some imprints are established in 
oocytes and others in sperm. At this stage, ICRs are targeted by two 
epigenetic marks, DNA methylation and histone modifications (DELAVAL 
et al. 2007). Dnmt3 enzymes are key enzymes for the acquisition of 
gamete-specific DNA methylation in both gametocytes (see 1.1.2.1) 
(TRASLER 2006). However, it is still unclear why some ICRs are 
methylated in the paternal germline and other in the maternal germline. 
Some proteins such as CTCF (which is not expressed in the testis) 
prevents the acquisition of methylation at H19 differentially methylated 
domain (DMD) in oocytes (ENGEL et al. 2006; FEDORIW et al. 2004; 
PANT et al. 2003). 
 
Following fertilization, the two parental genomes are exposed to a wave 
of demethylation followed by a wave of de novo methylation, both of 
which are resisted by imprinted loci (MORGAN et al. 2005). The 
mechanisms involved in the protection of ICRs at this stage are not 
elucidated (TRASLER 2006). The Dnmt1 and its isoform Dnmt1o are 
essential for the maintenance of methylation at imprinted loci (HOWELL 
et al. 2001; LI et al. 1992; TRASLER et al. 1996). Methyl-CpG binding 
domain (MBD) proteins as well as histone modifications might also play 
a role in the maintenance of ICRs DNA methylation by affecting 
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chromatin conformation (DELAVAL and FEIL 2004; MORGAN et al. 2005). 
At the H19 DMD in mice (IGF2/H19–ICR1 locus in humans), CTCF is 
required for the protection of the maternal allele from gain of 
methylation (ENGEL et al. 2006; PANT et al. 2003).   
 
The timing pattern of DNA replication of imprinted genes is also found 
to be erased in the germ line and then a parent-specific replication 
timing is established in late stage of gametogenesis and maintained 
throughout development (SHA 2008; SIMON et al. 1999). 
 
 
Figure 2: The imprinting cycle. In primordial germ cells, the previous 
imprinting marks are erased (1) at a very early stage and they will be 
re-established (2) at a later stage during gametogenesis according to 
individual sex (maternal-type marks in the oocytes and paternal-type 
marks in sperm). During early development, the imprinting marks 
should be maintained (3) while there is a wave of global demethylation 
followed by a wave of a de novo methylation. The imprinting marks are 
then maintained in somatic cells during development (Adapted from  
(REIK and WALTER 2001)).   
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Figure 3: DNA methylation dynamics during germ cell and 
preimplantation development: erasure in primordial germ cells (white), 
establishment of paternal (blue) and maternal (red) imprinting marks 
during spermatogenesis and oogenesis and maintenance of imprints 
after fertilization; the dotted lines represent the wave of demethylation 
of the paternal and maternal genomes which imprinted genes are 
protected from (Adapted from (REIK and WALTER 2001)). 
 
 
1.2 The IGF2/H19-ICR1 domain 
 
Human chromosome 11p15.5 contains a cluster of imprinted genes that 
play an important role in foetal and placental growth. This region 
comprises two neighbouring imprinted domains, the IGF2/H19 and the 
KCNQ1 domains, each of them under the control of its own imprinting 
center, ICR1 and ICR2 respectively (Fig. 4) (DELAVAL et al. 2006; 
GICQUEL and LE BOUC 2006; REIK and WALTER 2001). The IGF2/H19-
ICR1 domain includes two imprinted genes with reciprocal imprinting, 
IGF2 and H19, which are paternally and maternally expressed, 
respectively (IDERAABDULLAH et al. 2008). The mouse distal 
chromosome 7 region is orthologous to the human 11p15.5 region and 
displays the same imprinted genes (DELAVAL et al. 2006).  
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Figure 4: The imprinted cluster on human chromosome 11p15.5. It 
includes two imprinted domains, IGF2/H19-ICR1and KCNQ1-ICR2. 
Genes which are expressed from both alleles (not imprinted) are 
represented in brown, genes expression from the maternal allele are 
represented in red and genes expression from the paternal allele are 
represented in blue colour. ICR1 is methylated only on the paternal 
allele (green stars) and ICR2 is methylated only on the maternal allele.  
 
 
1.2.1 Overview of the IGF system 
 
The insulin-like growth factor system (IGF) is one of the most important 
endocrine and paracrine systems that regulates the complex process of 
foetal and placental growth. The IGF system consists of two ligands 
(IGF1 and IGF2), two IGF receptors (IGF1R and IGF2R) and a family of 
6 binding proteins (IGFBPs) from 1 to 6 (Fig. 5) (GICQUEL and LE BOUC 
2006). 
 
The biological effects of IGF1 and IGF2 are conveyed through the 
IGF1R receptor. IGF2 can also bind the insulin receptor (InsR). IGF2R 
controls IGF2 levels negatively by targeting IGF2 for lysosomal 
degradation and therefore inhibits foetal growth. The majority of IGFs 
(~80%) bind to the IGFBPs and acid-labile subunit (ALS) to form a 
ternary complex in the blood stream. More than 20% of IGFs are 
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associated with one of the IGFBPs in a binary complex and less than 
1% of the IGFs circulate in the free form (GICQUEL and LE BOUC 2006). 
 
 
Figure 5: Schematic illustration of the insulin-like growth factor (IGF) 
system.  The IGF system comprises IGF1, IGF2, IGF binding proteins 
(IGFBPs) 1 to 6, and the IGF receptors (IGF1R and IGF2R). IGF1 and 
IGF2 promote growth through interaction with IFG1R. IGF2 also 
promote growth through the insulin receptor (InsR). IGF2R is 
responsible for IGF2 clearance. The six IGFBPs bind both IGF1 and 
IGF2, but with different affinities. InsR = insulin receptor; ALS = Acid-
labile subunit (Adapted from (GICQUEL and LE BOUC 2006)).   
 
Several studies have been conducted to demonstrate the effect of IGFs 
on foetal and placental growth in mice (Fig. 6) (BAKER et al. 1993; 
GICQUEL and LE BOUC 2006). Inactivation of Igf1 or Igf2 results in foetal 
growth retardation (60% of normal body weight) and more severe 
growth retardation is caused by deletion of Igf1r (45% of normal body 
weight). Double knockouts of Igf2 and Igf1 or Igf2 and Igf1r result in a 
more severe growth retardation phenotype (30% of normal body 
weight). In contrast, Igf2 transactivation results in foetal overgrowth 
(130% of normal body weight). Interestingly, knockout of the Igf2 gene 
causes a reduction in placental size but neither Igf1 nor Igf1r mutations 
affect placental size. All these results show that both IGFs are involved 
in foetal growth and that IGF2 also contributes to placental growth. 
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Figure 6: Effects of disruption of one or a combination of genes of the 
IGF system on foetal growth in mice, expressed as a percentage of 
normal body weight. m– = Maternally disrupted allele; p– = paternally 
disrupted allele; –/– = both alleles disrupted (Adapted from (GICQUEL 
and LE BOUC 2006)). 
 
1.2.2 The IGF2 gene 
 
As previously discussed, the IGF2 gene plays a crucial role in foetal 
and placental growth.  IGF2 is imprinted in most tissues and is 
expressed from the paternal allele.  The human IGF2 gene consists of 
9 exons and its expression is controlled by 5 different promoters (P0 to 
P4) (Fig. 7) (FOWDEN et al. 2006). During foetal life, the expression of 
IGF2 is monoallelic in most tissues and driven by promoters P2, P3 and 
P4. After birth, the expression of the IGF2 gene is biallelic in the liver 
and driven by promoter P1. In the remaining tissues, the expression 
remains monoallelic under the control of promoters P3 and P4 
(FOWDEN et al. 2006). In addition, IGF2 itself contains two DMRs 
(DMR0 and DMR2), which carry the same DNA methylation marks as 
the ICR1 imprinting center and are methylated on the paternal allele 
(MURRELL et al. 2008).  
 
In the mouse, Igf2 is also imprinted (paternally expressed) but there are 
differences between the human and mouse IGF2 genes (Fig. 7). Firstly, 
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there are 4 promoters (P0 to P3) and no liver specific promoter. 
Secondly, the P0 promoter is specific of the placenta and is extremely 
important for placental transport (CONSTANCIA et al. 2002; FOWDEN et al. 
2006). This promoter P0 is not specific of the placenta in humans. 
Moreover, the mouse Igf2 gene displays three DMRs (DMR 0 to 2) and 
the mouse DMR1 behaves like the human DMR0 (MURRELL et al. 
2008).  
 
 
Figure 7: Schematic scale diagram of the mouse Igf2/H19 and human 
IGF2/H19. P: promoter; DMR: Differentially Methylated Region; DMD: 
Differentially Methylated Domain; ICR: Imprinting Control Region. The 
coding region of IGF2 is represented by black rectangles and the 
arrows represent start of transcription (Adapted from (MONK et al. 
2006)). 
 
 
1.2.3 The H19 gene 
 
Clusters of imprinted genes usually consist of at least one ncRNA and 
one or more protein coding genes. The H19 gene encodes a non 
translated RNA (BRANNAN et al. 1990) expressed only from the 
maternal allele in endodermic and mesodermic tissues (ZHANG and 
TYCKO 1992). The IGF2 and H19 genes have a reciprocal expression 
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(OHLSSON et al. 1994), under the control of the imprinting centre ICR1 
(DELAVAL et al. 2006; GICQUEL and LE BOUC 2006; REIK and WALTER 
2001). The expression of H19 gene is also regulated by a promoter 
which is differentially methylated, like ICR1, on parental alleles 
(GABORY et al. 2006). To understand the function of the H19 gene, 
different deletions of this gene and the imprinting centre have been 
performed in mice.  Mice in all these studies were viable and fertile, 
suggesting that the role of H19 during development is not crucial. 
However, these mice with deletions exhibited overgrowth (GABORY et 
al. 2006).  
 
Recently, the H19 nonccoding RNA (ncRNA) has been shown to 
function as a primary micro RNA transcript that might act as a  
posttranscriptional down regulator of specific messenger RNAs (CAI 
and CULLEN 2007). More recently, a new transcript named 91H RNA, 
which is expressed from the maternal allele within the H19 gene region, 
has been found to maintain IGF2 expression in trans (on the paternal 
allele), rather than affecting H19 expression (BERTEAUX et al. 2008).  
 
1.2.4 The epigenetic regulation of the reciprocal imprinting of the IGF2 
and H19 genes.    
   
1.2.4.1 Structure and chromatin organization of the ICR1domain 
The human IGF2/H19-ICR1 domain (H19 differentially methylated 
Domain (DMD) in mice) includes two reciprocally imprinted genes: the 
IGF2 and the H19 genes (Fig. 8). The reciprocal imprinting of the 
paternally expressed IGF2 (OHLSSON et al. 1994; OHLSSON et al. 1993) 
and the maternally expressed H19 (ZHANG and TYCKO 1992) genes 
depends on the differentially methylated region (ICR1) upstream from 
the H19 gene (FREVEL et al. 1999; IDERAABDULLAH et al. 2008).  This 
region is approximately 5 kilo-base (kb) in humans and 2 kb in mice 
and functions as an insulator (FILIPPOVA 2008; IDERAABDULLAH et al. 
2008). In humans, the wild-type ICR1 domain is arranged in two repeat 
units and each of them has A repeats (450 base-pairs (bp)) and B 
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repeats (400 bp). Unit one includes one A repeat (A1) and four B 
repeats (B1 to B4) and unit two consists of one A repeat (A2) and three 
B repeats (B5 to B7). The human domain displays 7 CTCF binding 
sites (FREVEL et al. 1999) (Fig. 8a). In mice, the H19 DMD region is 
arranged in four repeats (A1-4) which carry 4 CTCF binding sites. The 
sites of CTCF-binding sequences are highly conserved from drosophila 
to mice and humans (MOON et al. 2005). IGF2 and H19 share 
enhancers downstream of H19 that act on either gene according to 
parental origin (CHARALAMBOUS et al. 2004). 
At ICR1, CTCF binds the maternal unmethylated allele and prevents 
the IGF2 gene promoter from interacting with enhancers downstream 
from the H19 gene, resulting in transcriptional silencing of the maternal 
IGF2 gene (MURRELL et al. 2004). The methylation of CpG at ICR1 on 
the paternal allele prevents CTCF binding and allows IGF2 activation 
(FILIPPOVA 2008) (Fig. 8a).  
Therefore, a proper imprinting of Igf2 and H19 requires differential 
methylation at ICR1 on the parental alleles and CpGs mutation or 
deletion in this region leads to disruption of Igf2 and H19 imprinting 
(IDERAABDULLAH et al. 2008; LI et al. 2008; MURRELL et al. 2004).  
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Figure 8: IGF2/H19-ICR1 domain and parent-specific interactions. a) 
ICR1 consists of A and B repeats (rectangles). Every domain includes 
one A repeated sequence and 3 or 4 B repeated sequences (B4 is 
incomplete). Six of seven CTCF binding sites (violet triangles) are 
located in the B repeats. Maternal ICR1 is unmethylated (empty circles) 
and allows CTCF (violet oval) binding at the 7 CTCF binding sites. 
Methylation on the paternal ICR1 (filled circles) prevents CTCF binding. 
b) ICR1-IGF2 DMRs parent-specific interactions. On the maternal 
chromosome, the unmethylated ICR1 binds CTCF and interacts with a 
region at the 5‟ end of the IGF2 gene, DMR0. This loop positions IGF2 
away from the enhancers (which are common for H19 and IGF2) while 
H19 is close to the enhancers and suppresses and activates gene 
expression, respectively. On the paternal chromosome, methylated 
ICR1 interacts with methylated IGF2 DMR2. This loop positions IGF2 
close to the enhancers and allows IGF2 expression (Adapted from 
(MURRELL et al. 2004)).  
 
1.2.4.2 The CTCF protein  
The CCCTC-binding factor (CTCF) is a widely expressed zinc finger 
(ZF) nuclear protein and is known as a versatile transcription factor due 
to the combinatorial use of its ZFs to bind various DNA sequences 
(OHLSSON et al. 2001).  CTCF binds to a number of different sequences 
which are highly conserved  among vertebrates (OHLSSON et al. 2001). 
CTCF is encoded by the CTCF gene which maps to the human 
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chromosome 16q22 and consists of 10 exons (E1-E10). Exons E2-E9 
encodes for the 11 highly conserved zinc fingers (FILIPPOVA et al. 1996; 
OHLSSON et al. 2001) (Fig. 9a and b).  
 
 
Figure 9: Organization of the human CTCF gene (a) and its protein 
product (b). a) Filled boxes, protein coding exons; open boxes, 
untranslated exons; arrow, transcription start sites. b) The human 
CTCF protein consists of the DNA-binding domain, which is composed 
of 11 ZFs (OHLSSON et al. 2001). 
 
CTCF can regulate gene expression directly by acting as a classical 
transcriptional factor or indirectly by acting as a chromatin insulator 
(FILIPPOVA 2008). This indirect regulation is mediated through CTCF 
ability to form open or closed chromatin loop domains, which allow or 
block the access of promoters to the nearby enhancers (LI et al. 2008; 
MURRELL et al. 2004). The insulator activity of CTCF was first identified 
in the chicken β-globin locus (BELL et al. 1999) and later in H19 DMD 
(MURRELL et al. 2004; OHLSSON et al. 2001; PANT et al. 2003). Recently 
by using chromatin conformation capture, the chromatin interactions 
have been investigated in several studies. CTCF mediates physically 
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intrachromosomal interactions among cis-regulatory elements, within 
the IGF2/H19–ICR1 domain (FILIPPOVA 2008; LI et al. 2008). In 
addition, CTCF mediates interchromosomal interactions, where one 
allele from one chromosome interacts with another allele on another 
chromosome. For example, one allele of the mouse H19 DMD on 
chromosome 7 interacts with one allele of Wsb1/Nf1 on mouse 
chromosome 11 (KRUEGER and OSBORNE 2006; LING et al. 2006).  
Several models for the epigenetic control of insulators by organising 
higher order chromatin interactions have been proposed (FILIPPOVA 
2008; LI et al. 2008; MURRELL et al. 2004). At the unmethylated 
maternal allele, H19 DMD, which binds the CTCF protein, interacts with 
Igf2 DMR1 and Igf2 promoters and as a result the chromatin is 
organized in an inactive loop around the Igf2 gene (LI et al. 2008; 
MURRELL et al. 2004). The paternally methylated H19 DMD, which 
binds MBD proteins, interacts with the methylated Igf2 DMR2, resulting 
in activation of Igf2 (MURRELL et al. 2004). The ICR1 and DMRs 
interactions could be the same in humans. However, DMR0 instead of 
DMR1 interacts with ICR1 because DMR1 is absent in humans IGF2 
(MURRELL et al. 2008) (Fig. 8b). 
The crucial role of CTCF in imprinting regulation has been also 
identified at other imprinted loci, (but not all of them), such as KvDMR1 
and Rasgrf1. This data indicates a prevalent function of the CTCF 
protein in the regulation of genomic imprinting (FILIPPOVA 2008).  
 
The ICR1 insulator function of the CTCF protein might be altered 
through two mechanisms: mutation of CTCF binding sites at ICR1 or 
mutation of the CTCF ZFs (FILIPPOVA 2008). i) Disruption of CTCF 
function, therefore, can be a result of epigenetic defect at CTCF binding 
sites and consequently lead to loss of genomic imprinting. Mice studies 
have shown that mutation of the ICR1 at H19 DMD locus results in loss 
of Igf2 imprinting (ENGEL et al. 2004; FILIPPOVA 2008; LI et al. 2008; 
SAKATANI et al. 2005) and enhancers tumorigenesis (SAKATANI et al. 
2005). ii) Alternatively, mutation of the CTCF gene might disrupt the 
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CTCF functions by altering the binding of CTCF ZFs at its target 
sequences (FILIPPOVA 2008). Only point mutations of the CTCF ZFs 
have been found in several tumors including Wilms‟ tumors (FILIPPOVA 
et al. 2002). Interestingly, all these mutations lead only to change in the 
CTCF function rather than complete loss of CTCF function. Indeed, 
complete loss of CTCF function is not compatible with life (FILIPPOVA 
2008; FILIPPOVA et al. 2002). 
 
CTCF function is also regulated by post transcriptional modification 
(poly(ADP-riposy)lation). There is a functional link between poly(ADP-
riposy)lation and CTCF-dependent chromatin insulator function, where 
disruption of poly(ADP-riposy)lation leads to loss of insulator function 
not only at the ICR1 locus but also at most other CTCF target 
sequences  (FILIPPOVA 2008; YU et al. 2004). 
 
1.2.4.3 Other factors possibly involved in the control of imprinting at    
ICR1 
 
- MBDs 
Methylated CpG binding domain (MBD) proteins are likely candidates 
for recognizing DNA methylation marks and silencing transcription from 
imprinted loci. The MBD family includes 5 members, MeCP2 and MBD1 
to 4 and these MBD family members bind the methylated DNA with the 
exception of MeCP2 that binds both methylated and unmethylated 
DNA, with a preference for methyl-CpG-containing substrates 
(DHASARATHY and WADE 2008).  
 
Two MBD proteins have been shown to be involved in the regulation of 
imprinting at ICR1: MeCP2 and MBD3. MeCP2 has been found to bind 
to the methylated paternal ICR1 allele and other factors to form a 
repressor complex consequently silencing H19 expression (DREWELL et 
al. 2002). More recently, Reese et al. (REESE et al. 2007), has reported 
that MBD3 binds to the methylated ICR1 allele and its binding seems to 
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be specific for ICR1 where a depletion of MBD3 reduces the normal 
DNA methylation at ICR1 but not at other imprinted loci.  
- Antisense RNA 
At the ICR1 domain, IGF2 expression is also regulated by noncoding 
antisense transcript. Antisense transcripts have been proposed to 
regulate gene expression by cis- or tran-acting mechanisms (ROYO and 
CAVAILLE 2008). Recently, a new transcript named 91H RNA, which is 
expressed from the maternal allele within the H19 gene region, has 
been found to maintain IGF2 expression in trans (on the paternal 
allele), rather than affecting H19 expression (BERTEAUX et al. 2008).  
- Polycomb complex 
Polycomb group proteins play a role in silencing imprinted genes 
through modulation of chromatin structure. EZH2 belongs to one of the 
two polycomb protein complexes (PRC2/3) and recruits additional 
polycomb protein complexes, the binding of which contributes to 
formation of a repressive chromatin state (LEWIS et al. 2004; MAGER et 
al. 2003; UMLAUF et al. 2004). A recent study by Li et al. (LI et al. 2008), 
has suggested that binding of CTCF at ICR1 on the maternal allele 
recruits polycomb repressive complex 2 (PRC2) and induces H3K27 
methylation at Igf2 promoters. This chromatin complex around the Igf2 
promoters suppresses the expression of the Igf2 gene on the maternal 
allele. 
 
1.3 Role of the 11p15 region in development and diseases 
 
Most imprinted genes are associated with foetal and placental growth 
and aberrant imprinting leads to various growth disorders (ENKLAAR et 
al. 2006; GICQUEL and LE BOUC 2006; GICQUEL et al. 2008). This is well 
illustrated for the 11p15 region which is involved in the aetiology of the 
Beckwith-Wiedemann (BWS; OMIM 130650) and Silver-Russell (SRS; 
OMIM 180860) syndromes with foetal overgrowth and foetal growth 
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retardation, respectively (DELAVAL et al. 2006; GICQUEL et al. 2005; REIK 
and WALTER 2001). 
 
1.3.1 Mouse models 
 
To understand the role of the human 11p15 region in development and 
diseases, several studies have been conducted on the orthologous 
distal chromosome 7 region in mouse, in particular, the H19 DMD. 
Mouse models with transactivation of Igf2 or knockout of Cdkn1c 
develop foetal overgrowth and some other BWS features (BAKER et al. 
1993; ENKLAAR et al. 2006; GICQUEL and LE BOUC 2006). Mice with 
combination of these two mutations exhibit more severe BWS 
phenotypes (ENKLAAR et al. 2006). A deletion of the H19 DMR also 
results in foetal overgrowth, when maternally transmitted, due to 
biallelic expression of the Igf2 gene (DELAVAL et al. 2006). Conversely, 
invalidation of Igf2 results in foetal growth retardation (BAKER et al. 
1993; GICQUEL and LE BOUC 2006). Interestingly, point mutations of the 
CpG in the H19 DMD result in reduced Igf2 expression with foetal 
growth retardation when paternally transmitted. This seems to be 
caused by disruption of maintenance of DMD methylation and 
consequently establishment of insulator activity on the paternal allele 
which prevents Igf2 expression and allows biallelic H19 expression 
(ENGEL et al. 2004).  
 
1.3.2 Human models 
 
1.3.2.1 Foetal growth disorders 
 
As described above, the human chromosome 11p15 contains a cluster 
of imprinted genes which play a crucial role in the control of foetal 
growth and aberrant genomic imprinting of the 11p15 region has a 
pivotal role in both BWS and SRS foetal growth disorders (DELAVAL et 
al. 2006; GICQUEL et al. 2008; GICQUEL et al. 2005; REIK and WALTER 
2001). 
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Beckwith-Wiedemann syndrome is characterized by pre- and/or 
postnatal overgrowth, macroglossia, abdominal wall defects, 
organomegaly, body asymmetry, hypoglycaemia in the neonatal period, 
ear abnormalities and an increased risk of childhood tumours, in 
particular Wilms‟ tumor (ENKLAAR et al. 2006; GICQUEL et al. 2008). The 
phenotype of BWS patients is variable and children with BWS do not 
display all these features together (ENKLAAR et al. 2006; GICQUEL et al. 
2008). 
 
In contrast to BWS phenotypes, SRS is characterized by intra-uterine 
and postnatal growth retardation with spared cranial growth and body 
asymmetry. Other clinical features include a distinctive triangular face 
with prominent forehead and a pointed chin, clinodactyly of the fifth 
fingers, severe feeding difficulties, cafe´-au-lait spots, genital 
abnormalities and hypoglycaemia (ROSSIGNOL et al. 2008). 
 
1.3.2.2 Genetics of foetal growth disorders 
 
Unlike most other genetic syndromes, BWS and SRS can be caused by 
different genetic and epigenetic abnormalities, which lead to abnormal 
imprinting (ENKLAAR et al. 2006; GICQUEL et al. 2008) (Table II). 
Epigenetic defects are much more frequent in 11p15 growth disorders 
than other imprinting disorders and account for more than 60% of BWS 
and SRS cases. This suggests that the 11p15 region is particularly 
vulnerable to epigenetic cues (GICQUEL et al. 2008; ROSSIGNOL et al. 
2008). Loss of DNA methylation involving the ICR2/KCNQ1 domain 
results in 60% of BWS cases whereas gain of DNA methylation 
involving the IGF2/H19-ICR1 domain results in 10% of BWS cases 
(GASTON et al. 2001). Patients with gain of methylation at ICR1 have a 
higher risk of developing tumors particularly Wilms‟ tumor than patients 
belonging to other molecular subgroups (COOPER et al. 2005; GASTON 
et al. 2001). Gain of DNA methylation at ICR1 results in switch from the 
 
 
 
25 
maternal to the paternal epigenotype and consequently, biallelic 
expression of IGF2 and silencing of H19 (ENKLAAR et al. 2006). 
 
Maternal uniparental disomy (mUPD) for chromosome 7 accounts for 
approximately 10% of SRS cases and abnormalities of the 11p15 
region account for about 60 % of SRS cases (table II). Most 11p15 
SRS cases display epigenetic alterations (loss of ICR1 methylation on 
the paternal allele) and rare cases display maternal 11p15 duplication 
(ROSSIGNOL et al. 2008). Gicquel et al. (GICQUEL et al. 2005) reported 
the first cases of SRS with partial loss of methylation on the paternal 
ICR1 and H19 promoter. This switch from the paternal to the maternal 
epigenotype results in biallelic expression of the H19 gene and 
downregulation of the IGF2 expression (GICQUEL et al. 2005).  
 
Table II: Frequencies of 11p15 genetic and epigenetic defects in BWS 
and SRS disorders 
  
Molecular Defect BWS SRS 
 Parental  
origin 
Frequency Parental 
origin 
Frequency 
     
11p15 UPD paternal UPD 20%   
     
11p15 duplication paternal <2% Maternal <4% 
     
ICR1 epimutation gain of 
methylation 
10% loss of 
methylation 
60% 
     
ICR2 epimutation loss of 
methylation 
60%   
     
CDKN1C mutation maternal 5%   
 
UPD: uniparental disomy 
 
Whatever the methylation defect is, in either BWS or SRS, the DNA 
methylation defect has a mosaic distribution suggesting that the defect 
is a post-zygotic event (ROSSIGNOL et al. 2008). In agreement with this 
suggestion several studies reported a high incidence of discordant 
monozygotic twins in both BWS and SRS patients. Mosaicism could 
explain the high variability of the clinical phenotype among individuals 
in both BWS and SRS (ROSSIGNOL et al. 2008). 
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Although the human 11p15 DNA methylation defects in BWS and SRS 
caused by abnormal DNA methylation at ICR1 have been investigated 
in several studies, the mechanism(s) resulting in gain or loss of DNA 
methylation is still unknown in most cases. In a few familial BWS cases 
with a gain of methylation at ICR1, deletions within ICR1 have been 
reported (fig. 10); deletions result in a BWS phenotype only if the 
deletion is maternally-inherited (CERRATO et al. 2008; PRAWITT et al. 
2005; SPARAGO et al. 2004; SPARAGO et al. 2007). Subjects who inherit 
the deletion from the father do not display any phenotype and, more 
particularly, no SRS phenotype. These deletions (1.4 to 2.2 kb) 
removed from one to three CTCF binding sites and in most BWS 
cases, result in partial gain of methylation on the maternal allele and 
disturbance of genomic imprinting at the H19/IGF2-ICR1 locus 
(CERRATO et al. 2008; PRAWITT et al. 2005; SPARAGO et al. 2004; 
SPARAGO et al. 2007). The 2.2 kb deletion, which abolished 3 CTCF 
binding sites, did not result in gain of methylation (PRAWITT et al. 2005). 
It was proposed at this time that alteration of the spacing rather than 
loss of CTCF binding sites might be essential for ICR1 gain of 
methylation (PRAWITT et al. 2005). Very recently, Scott et al. (SCOTT et 
al. 2008) showed that a larger deletion of 5.3 kb removing both repeat 
blocks and six of the seven CTCF binding sites also results in gain of 
methylation at the seventh CTCF binding site. Interestingly, a 2.9 kb 
insertion adding two CTCF binding sites between the two ICR1 repeat 
blocks was also shown to result in gain of methylation (fig. 10). 
Although the insertion did not result in loss of CTCF binding sites or 
disturbance of the architecture within each block, there was a gain of 
methylation at ICR1 (SCOTT et al. 2008).  
 
Several attempts have been made to identify human ICR1 mutations in 
SRS cases but, neither mutations nor deletions have been found at the 
ICR1 locus (including 3 familial cases) (BARTHOLDI et al. 2008; BLIEK et 
al. 2006; BRUCE et al. 2008; YAMAZAWA et al. 2008).  
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Figure 10: Schematic diagram represents wild-type and mutations in 
humans IGF2/H19-ICR1 domain. a) Wild-type ICR1. b) Consequences 
of different deletions on the structure of ICR1 demonstrated in humans. 
Four deletions at ICR1 which abolish one CTCF binding site in 1.4 kb 
deletion (SPARAGO et al. 2004) or many CTCF binding sites (two sites in 
1.8 kb deletion (PRAWITT et al. 2005), three sites in 2.2 kb deletion 
(SPARAGO et al. 2007) and six sites in 5.3 kb deletion (SCOTT et al. 
2008). The deletions of 1.4 kb and 1.8 kb resulted in fusion of two 
repetitive domains and they were associated with a gain of methylation 
at ICR1. The 2.2 kb deletion resulted in an allele that was similar to one 
of the two repetitive units in terms of number of repeated sequences 
and the spacing of CTCF binding sites. This deletion (2.2 kb) did not 
cause any change in methylation status at ICR1. In contrast, there was 
an insertion (2.9) (SCOTT et al. 2008) that rearranges the repetitive units 
at ICR1. This insertion added two CTCF binding sites by fusion of one 
A and parts of two B repeats (B3 and B5) and it was association with a 
gain of methylated at ICR1.              
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1.4 Aims of the research 
Increasing evidence points towards the importance of genomic 
imprinting in development and diseases. The differentially methylated 
ICR1 mediates the reciprocal expression of the imprinted genes (IGF2 
and H19) and the zinc finger CTCF protein is required for the 
maintenance of differential methylation on the maternal allele. 
Epigenetic defects (gain or loss of DNA methylation) of the human 
ICR1 11p15 domain result in two opposite foetal growth disorders 
(BWS and SRS) depending on which parental allele is affected. A few 
deletions within ICR1 have been reported in familial BWS cases with 
ICR1 gain of methylation, however the mechanism(s) of the DNA 
methylation defects at ICR1 remains largely unknown in most BWS and 
SRS patients. The aim of this project was to extensively characterize 
the ICR1 domain and the CTCF gene in a series of BWS and SRS 
patients with gain and loss of methylation at ICR1, respectively. 
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2 SUBJECTS AND METHODS 
 
2.1 Subjects 
 
This project was conducted in compliance with institutional guidelines 
for research studies in human genetics and informed consent was 
obtained from participating individuals and/or their parents. The study 
population consisted of 37 patients with growth disorders caused by a 
DNA methylation defect of the 11p15 ICR1 domain. Blood DNA was 
available for all patients and DNA extracted from tongue tissue was 
available for two patients. The patients had already been diagnosed 
with a DNA methylation defects at ICR1 by Methyl-sensitive southern 
blotting of blood DNA. 
 
Twenty-one patients were diagnosed with BWS.  
 
BWS was diagnosed in all patients according to the clinical signs 
described in table III. The molecular investigation was performed in 
these patients between the age of 0 and 17 years. Analysis of the 
11p15 region by methyl-sensitive southern blotting showed a gain of 
methylation at ICR1 (CTCF binding site 3) and/or the H19 promoter and 
a normal methylation pattern at ICR2 in all BWS patients. One of these 
patients was diagnosed during foetal life and the parents decided to 
have the pregnancy terminated. 
 
Two BWS patients were siblings and the family pedigree is shown in 
Fig. 15a. Patient II-1 was born after 39 weeks of gestation from non 
consanguineous parents. The clinical presentation at birth included 
macrosomia, severe macroglossia, diastasis recti, nephromegaly, 
neonatal hypoglycemia and bilateral cryptorchidism. A sibling (II-3) 
displaying macrosomia, macroglossia and nephromegaly died at birth 
from unknown reason.  Another brother (II-5) displayed the same 
phenotype as patient II-1 including macrosomia and nephromegaly. 
Both patients (II-1 and II-5) underwent partial glossectomy within the 
first months of life. Their father I-1 was born with severe macrosomia 
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but did not display any other BWS phenotypes except a supernumerary 
nipple. There was no familial history evocative of BWS on the father‟s 
side (seven siblings). The two sisters (II-2 and II-4) as well as the 
mother (I-2) were born with a normal birth weight and were 
phenotypically normal. The pedigree was indicative of an X linked 
disorder but sequencing of the Glypican 3 gene ruled out a Simpson-
Golabi Behmel syndrome. Analysis of the 11p15 region showed an 
isolated gain of methylation at ICR1 and the H19 promoter in patients 
II-1 and II-5 and a normal methylation pattern in one of the sisters and 
the two parents. Seven of 20 (35%) BWS patients developed a Wilms‟ 
tumor (median age: 24 months; range: 14-39 months).  
 
Sixteen patients were diagnosed with SRS 
 
All SRS patients had a severe phenotype with severe growth 
retardation, relative macrocephaly at birth, facial dysmorphy and 
feeding difficulties; most of them displayed body asymmetry (table III). 
Molecular analysis was performed at the age of 0 to 7 years. Analysis 
of the 11p15 region showed a loss of methylation at ICR1 (CTCF 
binding site 3) and/or H19 promoter and a normal methylation status at 
ICR2. Two SRS patients were monozygotic twins and both of them had 
a co-twin who was unaffected (monozygotic discordant twining). 
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Table III: Clinical features of patients with BWS and SRS 
 
BWS SRS 
phenotype BWS patients phenotype SRS patients 
n 21 n 16 
sex F/M 11/10 sex F/M 7/9 
Macrosomia, n (%) 19/21 (90.5) IUGR, n (%) 16/16 (100) 
Macroglossia, n (%) 18/21 (86) post-natal growth retardation, n (%) 16/16 (100) 
abdominal wall defect, n (%) 13/21 (62) relative macrocephaly at birth, n (%) 16/16 (100) 
diastasis recti, n (%) 9 facial dysmorphy, n (%) 16/16 (100) 
umbilical hernia, n (%) 4 body asymmetry, n (%) 13/16 (81) 
Exomphalos, n (%) 0 feeding difficulties, n (%) 12/14 (86) 
organomegaly, n (%) 16/18 (89) developmental delay, n (%) 3/14 (21) 
body asymmetry, n (%) 7/21 (33) clinodactyly, n (%) 10/13 (77) 
hypoglycemia, n (%) 5/19 (26)   
Wilms‟ tumor, n (%) 7/20 (35)   
        
                        IUGR: intrauterine growth retardation  
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           2.2 Methods 
  
2.2.1 DNA extraction 
 
2.2.1.1 DNA extraction from blood tissues 
 
DNA was extracted from blood samples as described previously 
(MILLER et al. 1988). Briefly, blood samples (5-10 ml) were transferred 
in 50 ml Falcon tubes with 40 ml lysis buffer (20 mM TRIS pH 7.5 and 5 
mM MgCl2), incubated on ice for 15 min and centrifuged at 3000 rpm 
for 5 min at 4°C.  Supernatant was discarded and pellets were 
resuspended in 30 ml lysis buffer followed by centrifugation at 3000 
rpm for 5 min at 4°C.  The pellets were resuspended in 3.5 ml protein 
lysis buffer (20 mM TRIS pH 7.5, 400 mM NaCl and 2 mM EDTA).  The 
samples were digested overnight at 56°C with 200 µl of SDS 10% and 
80 µl of proteinase K (10 mg/ml). After digestion, 1 ml of saturated NaCl 
(6 M) was added to each tube and shaken for 15 sec, followed by 
centrifugation for 15 min at 4000 rpm. Supernatant containing the DNA 
was transferred to another 15 ml tube. Two volumes of absolute 
ethanol were added and the tubes were inverted several times until the 
DNA precipitated. The precipitated DNA was transferred to a 1.5 ml 
eppendorf tube and diluted in TE buffer (10 mM TRIS pH 7.5 and 1 mM 
EDTA) at a concentration of 1 µg/ µl. 
 
2.2.1.2 DNA extraction from tongue tissues 
 
Three to four slices (~1 mm each) of tongue tissue were washed twice 
with 1 ml of PBS. The tissue was resuspended in 1 ml of the following 
buffer (9 mM TRIS pH 8, 26 mM EDTA and 0.5% SDS) and 10 µl of 
proteinase K (20 mg/ml) and shaken gently. The mix was incubated 3 
hrs at 56°C then overnight at 37°C. The following day, 430 µl of 
saturated NaCl was added to the solution and mixed gently before 
centrifuged at 12000 rpm for 20 min at 4°C. The supernatant was 
transferred to a tube containing 3 ml of absolute ethanol to precipitate 
the DNA. The precipitated DNA was transferred to a 1.5 ml tube with 1 
ml of TE buffer and rotated for 12 hrs at room temperature.  
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2.2.2 Polymerase chain reaction (PCR) 
 
2.2.2.1 The IGF2/H19-ICR1 region 
 
 The ICR1 region is a very CG rich region which is particularly difficult 
to amplify. Therefore, different polymerase enzymes, different protocols 
of PCR and different enhancers have been investigated in this study. 
 
The primer sets used to amplify the target sequences to analyze ICR1 
and the CTCF binding sites 1 to 7, and the PCR conditions are 
summarized in table IV. Each PCR reaction mix contained 0.4 µM of 
each primer (forward and reverse), 0.3 mM of deoxynucleotides 
(dNTPs), 60-100 ng DNA and different concentrations of polymerase 
enzymes and PCR reagent buffers depending on the of primer sets 
used. The reactions were amplified using the Gene Amp PCR system 
9700 (Applied Biosystems). To investigate deletions in the ICR1 region, 
Long Range PCR amplifications were performed using the BIO-X-
ACTTM Long DNA Polymerase (BIOLINE, Boston, MA, USA) and the 
primers used by Scott et al. (SCOTT et al. 2008). Additional primers 
were designed along the ICR1 domain using Primer3 software 
(http://fokker.wi.mit.edu/primer3/input.htm) to finely characterize the 
deletion (table IV).  
 
The seven CTCF binding sites were investigated using primers 
previously described by Bliek et al. (BLIEK et al. 2006). CTCF binding 
sites from 1 to 3 were amplified by one PCR using GC-RICH Enzyme 
Mix (Roche Applied Science, Australia). CTCF binding sites 4 to 6 
region was more difficult to amplify thus different enhancers and GC-
RICH resolution solution (provided in the kit) concentrations (from 0.5 
to 2.5 M) were investigated. The best amplification was obtained by 
using 1 M of GC-RICH resolution solution. “Touch-down” PCR also 
helped to reduce the amplification of non-specific sequences. Standard 
PCR condition was conducted to amplify the CTCF binding site 7 using 
FailSafe DNA polymerase (EPICENTRE Biotechnologies, Australia).  
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2.2.2.2 The CTCF gene  
 
Standard PCR amplifications were performed to analyse all exons (1 to 
10) and flanking intronic regions of the CTCF gene using AmpliTaq 
Gold DNA polymerase (Applied Biosystems). Most primers used to 
amplify each target sequence have been previously described (CUI et 
al. 2001; YEH et al. 2002) and some additional primers have been 
designed using Primer3 software (table V).  Each PCR reaction mix 
contained 0.4 µM of each primer (Forward and Reverse), 0.3 mM of 
dNTPs, 1.5 mM of MgCl2 Buffer and 50-80 ng DNA.  
 
2.2.3 Gel electrophoresis and DNA purification 
 
Before purification, the PCR products of CTCF binding sites 1-3 and 4-
6 were separated on a 0.8 agarose gel at 100 volt (V) and the correct 
size fragment was cut from the gel. Small amount of CTCF binding site 
7 and CTCF exons PCR products were also electrophoresed in 0.8 
agarose gel at 100 V to check the PCR products and remaining PCR 
products were purified. The gel and PCR product purifications were 
performed using the Wizard® SV Gel and PCR Clean-Up System 
(Promega, Madison, WI, USA) according to the manufacturer‟s 
instructions. 
 
2.2.4 Sequencing and sequencing analysis 
 
Different forward and reverse primers were used in the sequencing to 
analyse the different amplified regions (table IV and V). Sequencing 
was performed by the sequencing lab at the Baker IDI Heart and 
Diabetic Institute (Melbourne, Australia) using the BigDye Terminator 
V3.1 cycle sequencing kit on the ABI 3100 automatic sequencer 
(Applied Biosystems, Foster City, CA, USA). The sequencing results 
were analyzed with the Chromas 1.45 software (Applied Biosystems, 
Foster City, CA, USA). 
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2.2.5 Bisulfite treatment of DNA  
 
DNA methylation patterns at ICR1 in BWS and SRS patients with ICR1 
mutations and in control samples were analysed by bisulfite 
sequencing. Treatment of DNA with bisulfite results in converting all 
unmethylated cytosines residues to uracils while 5-methylcytosine 
residues remain unaltered. Bisulfite treatment thus gives different DNA 
sequences depending on wether the cytosine of a CpG nucleotide is 
originally methylated or unmethylated.  
 
Genomic DNA was bisulfite modified using the EZ DNA modification kit 
(Zymo Research, Orange, CA, USA) according to the manufacturer‟s 
instructions. Briefly, 5 µl of M-Dilution buffer were added to 1 µg of 
genomic DNA from blood or tongue tissues in a total volume of 50 µl. 
After incubation of the reaction mix at 37°C for 15 min, 100 µl of CT 
conversion reagent (EZ DNA modification kit) was added to each 
sample and incubated in the dark for 16 hours (hrs) at 50°C. Bisulfite 
treated DNA was washed using reagents provided in the kit and then 
desulphonated by adding 200 µl M-desulphonation Buffer (EZ DNA 
modification kit). Modified DNA was washed twice and then eluted in 20 
µl H2O.  
 
2.2.6 Amplification of bisulfite-treated DNA 
 
After treatment of samples by bisulfite, specific primer sets were used 
to amplify each CTCF binding site sequence (1 to 7) (table VI). Each 
primer set was designed to be bisulfite-specific and to amplify both 
methylated and unmethylated alleles. Therefore, all the cytosines were 
converted to thymines in the primers such that they did not amplify non-
bisulfite treated DNA. In addition, the primers did not include CpG in 
their sequences so they amplified both methylated and unmethylated 
sequences. Some PCR primers were designed using the MethPrimer 
web based design program (http://www.urogene.org/methprimer/) and 
others were previously reported (table VI). Standard PCR amplification 
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was performed using 1 U HotStar DNA polymerase (Qiagen, Australia), 
0.4 µM of each primer (forward and reverse), 0.3 mM of dNTP, 1 X 
buffer (provided in the kit) and 2 µl of bisulfite treated DNA. Following 
the size confirmation of PCR fragments by agarose gel, the fragments 
were cloned and sequenced. 
 
2.2.7 Cloning and sequencing of PCR products 
 
To characterize the 1.8 kb deletion precisely, the PCR product from 
PCR with primers ICR1 _4426_5166_F (4426 F) and 
ICR1_6135_6969_R (6969 R) was cloned and sequenced. Cloning was 
also conducted after treatment of the DNA by bisulfite to look at 
individual methylation status from one allele of one cell.  
 
After size confirmation of the fragments of different PCR products by 
electrophoresis, the PCR products were cloned using TOPO TA 
Cloning® Kit (Invitrogen, Carlsbad, CA) according to the manufacturer‟s 
recommendations. In brief, 2 µl from each PCR product was cloned into 
a pCR®II-TOPO vector and incubated for 20 min at room temperature.  
Two µl of the above mixture was added into a vial of „One Shot® 
DH5α™-T1R Competent Cells and incubated on ice for 30 min before 
transformation. The cells were heat-shocked at 42°C for 45 seconds 
(sec). Following Transformation, the cells were placed on ice and 250 
µl of S.O.C media (provided in the kit) was added then the mixtures 
were shaken at 250 rpm for 1 hr at 37°C.  Fifty to sixty µl of each 
transformation was spread on LB plate containing 50 µg/ml kanamycin 
and 40 mg/ml of X-gal (for blue/white screening) and the plates were 
incubated at 37°C overnight. The following day, 10-12 white single 
bacterial colonies per sample was transferred to 15 ml tubes containing 
3 ml of LB medium with 50 µg/ml kanamycin. Culture media were then 
incubated at 37°C overnight. The recombinant plasmid DNA from each 
colony was purified for each sample using the Wizard® Plus SV 
Minipreps DNA purification System kit (Promega, Madison, WI, USA) 
as described in the kit protocol.  
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Inserted DNA in the plasmids was sequenced with M13 Forward (-20) 
or M13 Reverse primer (provided in the kit). Sequencing was 
performed by the sequencing laboratory at the Baker IDI Heart and 
Diabetic Institute (Melbourne, Australia). The sequencing results were 
analyzed with the Chromas 1.45 software (Applied Biosystems, Foster 
City, CA, USA).  
 
Analysis of the methylation pattern for all DNA fragments was 
performed using QUMA Quantification tool (http://quma.cdb.riken.jp/). 
Each CTCF binding site sequence for each patient was compared to a 
non-treated DNA sequence and the percentage of methylation was 
estimated using the following formula: 
 
Methylation index (%) = number of methylated CpG sites/number of  
                                       total CpG sites X 100 
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Table IV: Primers and PCRs conditions used for analysis of the human ICR1 region 
 
Primers PCR Primers References 
Name Sequence 
Position
* 
Purpose Polymerase 
Buffer &/or 
enhancer 
Cycles 
Annealing 
temp  
ICR1 scott H1 F 5'-CACATCTGCCTCCAGGTGAC-3' 2704 
amplification 
    
(Scott et al. 2008) 
ICR1 scott H1 R 5'-GAGTGTCAAAGCCGTGAAGG-3' 9241     
ICR1_2819_3597_F** 5'-ACCCAGGCACTCACCATTAC-3' 2819       
ICR1_2819_3597_R** 5'-CCAAATTTCCTGGGAGACTG-3' 3597       
ICR1_3414_4182_F** 5'-TCACCCCCAGGAGAGTAGTG-3' 3414       
ICR1_3414_4182_R** 5'-CCAGCCTGGATGATAAGAGC-3' 4182       
ICR1_3981_4685_F** 5'-CCTGGGAAAGGGCTGTTATT-3' 3981 Amplification to BIO-X-ACT™ 1X Hi-Spec    
ICR1_3981_4685_R** 5'-GTTCTTTGGGGTCCAAGTCA-3' 4685 characterize the Long Mix (2U) 1XOptiBuffer 40 58°C  
ICR1_4426_5166_F** 5'-CCGGCCGATTTTCTGTAATA-3' 4426 1.8 kb deletion BIOLINE 2 mM MgCl2    
ICR1_4426_5166_R** 5'-CCGAGATCCCTATCATCCAA-3' 5166 in patient KL41      
ICR1_5662_6459_F** 5'-TTCCCCTTCTGTCTCACCAC-3' 5662       
ICR1_5662_6459_R** 5'-CTGATTCCAGCAGCACAGAG-3' 6459       
ICR1_6135_6969_F** 5'-TCAGTGCAGGTTTGAGATGC-3' 6135       
ICR1_6135_6969_R** 5'-CACTTCACTGTCCCCCAAGT-3' 6969       
ICR1_7892_8782_F** 5'-GAGGCTTCTCCTTCGGTCTC-3' 7892       
ICR1_7892_8782_R** 5'-CCGGAAATACAAATGCTCCA-3' 8782       
CTCFSITE 1-3 F 5'-GCCCATCTTGCTGACCTCAC-3' 4825 Amplification GC-rich (2U) 
1.5M GC-RICH 40 62 °C (Bliek et al. 2006) 
CTCF SITE 1-3 R 5'-AGAAGACCTCCGAGAACCCTG-3' 5834 & sequencing Roche 
CTCF SITE 2 R 5'-AATGTGGCTCCCATGAGTG-3' 5461 sequencing     (Bliek et al. 2006) 
CTCF SITE 4-6 F 5'-GGTAGGACCCTTGTACGAGCC-3' 6864 amplification GC-rich (2U) 1.5 M GC-RICH 10 72 °C *** 
(Bliek et al. 2006) 
CTCF SITE 4-6 R 5'-GACCTGAAGATCTGGTGCGG-3' 8121 & sequencing Roche 
1 M GC-RICH 
resolution 
40 62 °C 
CTCF SITE 5 R 5'-AGAAGGGTTTCACACTAGGGCCG-3' 7829 sequencing     (Bliek et al. 2006) 
CTCF SITE 7 F 5'-ATTTCCTGAGTCTCCCCTTGG-3' 8785 Amplification FailSafe (1.25) 
EPICENTRE 
Biotechnologies 
1X buffer D 50 60 °C (Bliek et al. 2006) 
CTCF SITE 7 R 5'-TCGGCAAACCCTCTGTTCC-3' 9137 & sequencing 
*:    According to the reference sequence AF 125183 
**:    Primers designed using Primer3 software (http://fokker.wi.mit.edu/primer3/input.htm) 
***: Touch down PCR 1 °C / cycle for the 10 first cycles 
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        Table V: Primers and PCRs conditions used for the analysis of the human CTCF gene 
 
Primers PCR 
Primers  
References 
Name Sequence Fragment size Purpose Polymerase 
Buffer &/or 
enhancer 
Cycles 
Annealing 
temp 
 
CTCF1 YehF 5‟-TAAATATGGAGGAACAGCC -3‟  sequencing     (YEH et al. 2002) 
CTCF1 CuiF 
CTCF1DR 
5‟-CATCAAGAGCACATGTCTGTTGTG -3‟ 
5‟-TGCACTGTGTTGTATGCTTATCC -3‟ 
1007bp 
amplification 
& 
sequencing 
 
AmliTaq Gold 
Polymerase 
(2U) 
1X green 
buffer 
& 
1.5 mM 
MgCl2 
40 
 
60 °C 
(CUI et al. 2001) 
CTCF2 F* 
CTCF2 R* 
5‟-CACTTTGAAACTCTGCAGCAA -3‟ 
5‟-TCCCGCTGGAGTCAGCTT -3‟ 
300bp 60 °C  
CTCF3 F* 
CTCF3 R* 
5‟-TGCCACACATTGAACTCTGTC-3‟ 
5‟-TCATGGTCTGCCTAAGAGAGAT-3‟ 
252bp 58 °C  
CTCF4 CuiF 
CTCF4 CuiR 
5‟-GCTTTTGTGCCTAACCTACTGTGC-3‟ 
5‟-CTGAACAACGAATTCAGAGGATATGC-3‟ 
368bp 60 °C (CUI et al. 2001) 
CTCF5 CuiF 
CTCF5 CuiR 
5‟-TCTCTGTGGTGTAGCTATTCTG-3‟ 
5‟-TGTTATGAGAGTCAGAAGGTGAAGT-3‟ 
350bp 60 °C (CUI et al. 2001) 
CTCF6 F* 
CTCF6 R* 
5‟- TTCACATTACCCTGGGCTTT-3‟ 
5‟-ACCGAGAAAGCACCAACAAC -3‟ 
234bp 58 °C  
CTCF7 CuiF 
CTCF7 CuiR 
5‟-CGTGTGGAGTCTAGACCTAGCTTGG-3‟ 
5‟-CCATGCTCTGCAGAGGAAGAC-3‟ 
377bp 58 °C (CUI et al. 2001) 
CTCF8F* 
CTCF8R* 
5‟-CTTCCAATCTGATCTTAGCTTTTT -3‟ 
5‟-ACTGGAAACTGGGCTCCAA -3‟ 
255bp 58 °C  
CTCF9 CuiF 
CTCF9 CuiR 
5‟-TTCATCTTCCACCACCCTTCTC-3‟ 
5‟-GACTTCCTCAGATGTTCCTCAGT-3‟ 
405bp 60 °C (CUI et al. 2001) 
CTC10 YehF 
CTC10 YehR 
5‟-ATTCTTGGGGCTTTAATGGAC-3‟ 
5‟-ATGCGGGCCGTTTAAACACAG-3‟ 
274bp 60 °C (YEH et al. 2002) 
 
            *: Primers designed using Primer3 software (http://fokker.wi.mit.edu/primer3/input.htm) 
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        Table VI: Primers and PCRs conditions used for the analysis of the human ICR1 region following bisulfite treatment.  
 
Primers PCR 
Primers 
 references 
Name Sequence Position* Purpose Polymerase Cycles 
Annealing 
temp 
 
TAKAICTS1F TAKAICTS1R 
5'-GTATTTTTGGAGGTTTTTTATTTAG-3' 
5'-ACACCTAACCTAAAAAACCTAAAAC-3' 
4773 
5004 
amplification & 
sequencing 
HotStar (1U) 
Qiagen 
38 
50 °C 
(TAKAI et al. 
2001) 
TAKAICTS2F TAKAICTS2R 
5'-AGGTGTTTTAGTTTTTTGGATGATA-3'       
5'-CCATAAATATTCTATCCCTCACTA-3' 
5131 
5451 
TAKAICTS3F TAKAICTS3R 
5'-GGTTTTTGGTAGGTATAGAAATTG-3'       
 5'-CACCTAACTTAAATAACCCAAAAC-3' 
5593 
5811 
TAKAICTS4F 
BIS CBS4 R 7302** 
5'-GTTTTTGGTAGGTTTAAGAG-3' 
5'-CACCCTAAAATAAATCAAACACA-3' 
7026 
7302 
TAKAICTS5F 
TAKAICTS5R 
5'-TTTTGTAGGGTTTTTGGTAG-3' 
5'-TCCCATAAATATCCTATACCTC-3' 
7424 
7693 
55 °C 
 
ICR1-5962BT 
ICR1-6413BT 
5'-TGTTGAAGGTTGGGGAGATGGGA-3' 
5'-CCCAAACCATAACACTAAAACCCTC-3' 
7734 
8185 
(ULANER et al. 
2003) 
CTCFBS7CG2009F** 
CTCFBS7CG2009R ** 
5'-TTTTTTATAATGTTTGGAGTAGGAG-3' 
5'-TCTCAAACTTTTCCATAAATAAACC-3' 
  
 
 
            *:  According to the reference sequence AF 125183 
            **: Primers designed using the MethPrimer web based design program (http://www.urogene.org/methprimer/) 
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3 RESULTS 
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3 RESULTS 
 
3.1 Analysis of the IGF2/H19-ICR1 domain  
 
3.1.1 Identification of mutations in the ICR1 domain   
 
3.1.1.1 Long range PCR 
 
Long range PCR was conducted on 21 BWS and 16 SRS patients with 
primers spanning the whole ICR1 (ICR1 Scott H1 F and R) which 
allowed to identification of a deletion in one BWS case (KL41) (Fig. 
11and 12). Analysis of the PCR amplification products on an agarose 
gel highlighted the deletion of approximately 2000 bp in this patient 
(Fig. 12). Because it was difficult to sequence the complete allele 
carrying the deletion (~4500 bp), additional primers were used to 
localize more precisely the deletion. From PCRs with different primers 
(Fig. 12b), it was clear that the deletion started between 4426 and 5662 
and ended between 6459 and 6969 (according to the reference 
sequence AF 125183). Then, a PCR was performed using 4426 F and 
6969 R primers, which gave the shortest fragment with both alleles, to 
identify the exact start and end of the deletion. By cloning and 
sequencing this PCR product (including the normal and deleted 
alleles), it was found that the deletion started between 5067 and 5086 
and ended between 6900 and 6919 (minimum size 1814 bp and 
maximum size 1852 bp) (Fig. 12c). This deletion was generated by 
recombination of the B6 and the B3 repeats, removing almost the entire 
B6 repeat and also the B5, B4 and A2 repeats. Recombination of the 
B6 with the B3 repeats results in the loss of CTCF binding sites 2 and 3 
(Fig. 12c). Parental analysis showed that this deletion was maternally-
inherited.  
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Figure 11: Analysis of the ICR1 domain. a) Primer sets for long range 
PCR and CTCF binding sites (CTCF BSs). Forward primers (F) and 
reverse primers (R). b) Agarose gel of long range PCR products (6537 
bp) for BWS and SRS patients. One BWS displayed a deletion, 
indicated by red arrow, c) Agarose gel of PCR products of CTCF BS1-3 
and CTCF BS4-6. The fragments 1009 bp of the CTCF BS1-3 and 
1257 bp of the CTCF bS 4-6 were cut, purified and sequenced in all 
patients and control samples (All numbers are numbered according to 
AF125183).  
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Figure 12: ICR1 analysis in BWS case KL41. a) Pedigree of the family. 
b) Identification and characterization of the deletion.  Identification of the 
deletion, using ICR1 scott H1F and R primers, is showed on a 0.8% 
agarose gel. The 6537 bp band corresponds to the normal allele 
whereas the ~4537 bp band corresponds to the deleted allele. Additional 
primers were used to characterize the break points of the deletion. The 
start and the end of the deletion were identified by the primers which are 
represented in red colour. c) Localization of the deletion: Position of the 
breakpoints (indicated by arrows at 5067/5086-6900/6919) has been 
identified after cloning and sequencing both alleles and is highlighted on 
the chromatogram. The deletion deletes two CTCF binding sites (2 and 
3) (All numbers are numbered according to AF125183). 
 
3.1.1.2 Sequencing analysis of ICR1 
 
Direct sequencing of the ICR1 domain was performed for all BWS and 
SRS patients using 3 PCR conditions for each primer sets, CTCF BS1-
3 F and R (1009 bp), CTCF BS4-6 F and R (1257 bp) and CTCF BS7 F 
and R (352 bp) (Fig. 11a and c). Sequencing analysis of these regions 
allowed to identify a very small deletion in one BWS patient (CF32), 
that was not found in control samples (n=50). This deletion was 8 bp 
long (residues 7277-7284 according to the reference sequence 
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AF125183) within the B3 repeat. This deletion was outside a CTCF 
binding site, 116 bases 3‟ of the fourth CTCF binding site and did not 
remove any CTCF binding site (Fig. 13). The 8 bp deletion was 
maternally-inherited. 
 
 
Figure 13: ICR1 deletion in BWS case CF32. a) Pedigree of the family. 
b) Identification and localization of the deletion. The 8 bp deletion is 
located within the B3 domain and breakpoints are indicated by arrows 
at 7277 and 7284 (according to the reference sequence AF125183). 
The deletion was outside a CTCF binding site, 116 bases 3‟ (green 
letters in the sequences) of the fourth CTCF binding site (capital letters 
in the sequences) and did not delete any of the seven CTCF binding 
sites.  
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ICR1 analysis identified a single nucleotide variation in one SRS patient 
(PE18), outside a CTCF binding site, (G->T 9048, according to the 
reference sequence AF 125183). This variation was not found neither 
in a control population (n=50) nor in all public databases and is 
therefore unlikely to be a polymorphism (Fig. 14).  
Deletions and the single nucleotide variation and their parental 
inheritance when available are summarized in table VII. 
 
 
Figure 14: ICR1 analysis in SRS case PE18. a) Pedigree of the family. 
b) Identification and localization of the heterogenous variation (G->T 
9048, according to the reference sequence AF125183). The variation 
was outside of a CTCF binding site (CTCF BS), 164 bases 3‟ from the 
seventh CTCF binding site (capital letters in the sequences). 
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Long range PCR and direct sequencing of the seven CTCF binding 
sites in the familial case (BWS brothers (LB43 and LS44), with gain of 
methylation at ICR1), ruled out a deletion in this familial case (Fig. 15).  
 
 
Figure 15: Familial BWS case. a) Pedigree of the familial BWS cases. 
b) Long range PCR for the two brothers (II-1 and II-5), and a 0.8% 
agarose gel ruling out a deletion in this family.  
 
 
 3.1.1.3 Identification of nucleotide variations in the control population 
 
The ICR1 11p15 region is genetically highly variable and displays a 
number of single-nucleotide polymorphisms (SNPs). Sequencing and 
analysis of this region in our cohort of patients allowed to identify new 
genetic changes that were not documented as polymorphisms (position 
5269 in a SRS patient (SA21) and 7648 in a BWS patient (TL) 
according to the reference sequence AF 125183). Therefore, we 
sequenced a cohort of 50 control samples to evaluate precisely the 
frequency of these new variations in the normal population (4.0% for 
the SNP position 5269 and 6.3% for the SNP position 7648). The 
sequence of control samples also allowed us to document the 
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frequency of other previously described SNPs, which were not 
available in public databases. The frequency of the SNPs is 
summarized in table VIII. 
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                      Table VII: Deletions and single nucleotide variation in BWS and SRS patients 
Patient Phenotype Variation 
Position 
(Acc AF125183) 
Localization Transmission 
% Heterozygosity 
 x/n chromosomes 
CF32 BWS del 8 bp 7277-7284 B3/ 3‟ of  CTCFBS4 maternal 0/100 
KL41 BWS Del ~ 1.8 kb 5067/5086-6900/6919 B6>B3 maternal  
PE18 SRS G->T 9048 3‟ of CTCFBS7 NA 0/100 
 
                       NA: not available 
 
 Table VIII: Frequency of polymorphisms at the ICR1 region in a control population  
SNP number Variation Position  (Acc. AF125183) 
NCBI frequency 
% heterozygosity 
% Heterozygosity in our 
control population(n=50) 
rs57889360 GA 5165 unknown 2.0% 
(CERRATO et al. 2008) TC 5198 unknown 8.2% 
This study* TC* 5269  unknown 4.0% 
rs4930101 AC 7313 unknown 31.9% 
rs2525882 AG 7342 unknown 29.2% 
rs2735970 AG 7357 unknown 32.6% 
rs2735971 AG 7523 unknown 29.2% 
rs2735972 CT 7591 unknown 29.2% 
This study* CA* 7648  unknown 6.3% 
(CERRATO et al. 2008) AG 7679 unknown 18.4% 
 
*: new polymorphisms 
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          3.1.2 ICR1 DNA methylation analysis  
 
Since a gain of methylation at ICR1 in patients with ICR1 deletion has 
been controversial, we decided to analyze the DNA methylation status 
in our BWS patients carrying an ICR1 deletion (patients CF32 and 
KL41). In addition, the DNA methylation profile was investigated in the 
SRS patient with the single nucleotide variation at ICR1 (PE18). In this 
study, DNA methylation status was analyzed by bisulfite sequencing 
allowing the analysis of each CpG in the CTCF binding sites and their 
flanking regions.  
 
Bisulfite sequencing demonstrated a gain of methylation at CTCF 
binding sites 1, 4, 6 and 7 (methylation indexes from 73% to 95%) in 
BWS patient KL41 (Fig. 16b). CTCF binding sites 2 and 3 were also 
investigated in KL 41 and the results indicated that both sites were 
methylated (98% and 90% respectively) on the wild type paternal allele, 
because these two sites were abolished on the maternal allele that 
carries the deletion. 
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Figure 16: Methylation status of ICR1 in BWS case KL41 and a control 
individual. a) DNA methylation profiles of some CTCF binding sites 
(CTCF BS) and flanking regions determined by bisulfite sequencing in 
control sample (in blood cells). Each line corresponds to an individual 
cloned DNA fragment and each circle to a CpG dinucleotide. Methylated 
CpGs are indicated by filled circles and unmethylated CpGs by open 
circles. The CpG included in the CTCF binding sites are framed. Parental 
alleles were distinguished by known single-nucleotide polymorphisms at 
CTCF binding sites 1, 4 and 5. b) DNA methylation profiles of CTCF 
binding sites 1-4, 6-7 and flanking regions in KL41 patient (in blood 
cells). CTCF binding sites 2 and 3 were originated from the paternal 
allele, because these two sites are abolished on the maternal allele that 
carried the deletion (All numbers are numbered according to AF125183). 
 
Bisulfite sequencing also showed a complete gain of methylation at 
CTCF binding sites on the maternal allele for BWS patient CF32. We 
were able to distinguish the two parental alleles and to show that the 
maternal deleted allele was methylated (Fig. 17). The extent of 
methylation was similar (methylation index more than 96% for patient 
CF32) at the seven CTCF binding sites and the H19 promoter. 
 
These results indicate that a deletion at ICR1 (even a very small 
deletion which does not involve a CTCF binding site) results in a gain of 
methylation at ICR1.  
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Figure 17: Methylation status of ICR1 in BWS case CF32. DNA 
methylation pattern in all CTCF binding sites (CTCF BS) 1-7 and 
flanking regions in patient CF32 (tongue tissue). Maternal (abnormal) 
and paternal (wild-type) alleles were distinguished by known single-
nucleotide polymorphisms (All numbers are numbered according to 
AF125183). 
 
Conversely, there was a nearly complete loss of methylation on the 
paternal allele for PE18 patient (SRS patient with the single nucleotide 
variation) in CTCF binding sites 2, 4 and 6 (Fig. 18) (methylation 
indexes were between 0% and 4%). A known SNP (7192) in the 
flanking region of the CTCF binding site 4, showed that both alleles are 
unmethylated, indicating a loss of methylation on the paternal allele. In 
the other CTCF binding sites (1, 3 and 5) only one colony in each one 
of them was methylated and no SNPs in this patient were available to 
identify if these colonies come from one allele or from different alleles.  
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Figure 18: Methylation status of ICR1 in SRS case PE18. DNA 
methylation profiles of CTCF binding sites 1-6 and flanking regions 
determined by bisulfite sequencing in blood cells. Paternal allele (with 
loss of methylation) and Maternal (wild-type) alleles were distinguished 
by known single-nucleotide polymorphisms (All numbers are numbered 
according to AF125183). 
 
3.2 Mutation analysis of the CTCF gene 
 
CTCF binds the seven CTCF binding sites using its ZFs to prevent the 
de novo methylation at IGF2/H19-ICR1. Some CTCF mutations have 
been described in several tumors, including Wilms‟ tumors (FILIPPOVA 
et al. 2002), which altered CTCF DNA-binding specificity (FILIPPOVA 
2008). Therefore, we looked for mutations of the CTCF gene, that could 
affect the structure of ZFs, in all BWS patients with gain of methylation 
at ICR1 (n=21) (Fig 19). We sequenced all exons and flanking intronic 
regions of the CTCF gene. No change in the coding sequence of the 
CTCF gene was found in any of these patients. Only one of the two 
polymorphisms, according to the accession number    NC_000016, was 
found in the exon 10 3‟UTR (rs6499137, G/T) in 3 patients. These data 
suggest that CTCF gene mutation is not a common cause of gain of 
methylation at ICR1 in BWS. 
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Figure 19:  Analysis of the CTCF coding sequences. Filled boxes, 
protein coding sequences (10 exons which were sequenced in all BWS 
patients); open boxes, untranslated exons; arrows primer sets Forward 
(F) and reverse (R).  
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4 DISCUSSION 
 
As described in the literature, the 11p15 H19/IGF2-ICR1 is methylated 
exclusively on the paternal allele and interacts with the zinc finger 
protein CTCF on the unmethylated maternal allele at seven CTCF 
binding sites. The methylation status on the ICR1 mediates the 
reciprocal imprinting of the two imprinted genes in this locus, IGF2 and 
H19. Abnormal methylation at ICR1 results in the disturbance of the 
reciprocal imprinting of these genes and two opposite growth disorders, 
BWS and SRS.  ICR1 is arranged in two blocks which contain highly 
repetitive sequences. Both the repetition of the sequences and the high 
content in CpG dinucleotides make this region particularly difficult to 
analyse. Therefore, the first step of this project was to optimize the 
PCR conditions. We evaluated different Taq polymerases, different 
enhancers (betaine, Dimethyl Sulfoxide (DMSO) and commercial 
enhancers) and different protocols of PCR (touch down) to achieve for 
each domain the best conditions of amplification.  
 
Abnormal methylation of the 11p15 IGF2/H19-ICR1 imprinted domain 
accounts for approximately 10% of BWS patients (ENKLAAR et al. 2006; 
GASTON et al. 2001) and 60% of SRS patients (ROSSIGNOL et al. 2008). 
Little information is available regarding the mechanism of ICR1 DNA 
methylation defects. Only a few studies have addressed the 
relationship between ICR1 mutations and DNA methylation defect at 
IGF2/H19-ICR1 locus in humans. Deletions (1.4 to 2.2 kb) removing 
part of ICR1 have been described in a few BWS familial cases with 
dominant maternal transmission (CERRATO et al. 2008; PRAWITT et al. 
2005; SPARAGO et al. 2004; SPARAGO et al. 2007). These deletions do 
not affect the phenotype when paternally inherited. No smaller 
deletions or mutations within ICR1 have been described in 12 BWS 
patients not exhibiting deletions (CERRATO et al. 2008) and alter 
construction of the 11p15.5 haplotypes, the authors suggested that the 
epimutation in these 12 individuals arose independently of the 
sequence context (CERRATO et al. 2008). Very recently, Scott et al. 
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(SCOTT et al. 2008) showed that constitutive ICR1 imprinting 
abnormalities (including a 5.3 kb deletion and a 2.9 kb insertion) can 
also occur in apparently sporadic Wilms‟ tumors. All together, ICR1 
deletions account for only a small proportion of BWS cases. Even less 
is known regarding the mechanism of ICR1 loss of methylation in SRS 
patients. Engel et al. (ENGEL et al. 2004) previously showed that 
mutations of CpG dinucleotides in the mouse H19 DMD result in a 
growth retardation phenotype when paternally inherited and loss of 
methylation of the paternal allele as seen in SRS patients. However, 
attempts to identify ICR1 mutations in SRS patients, including familial 
cases, were negative (BARTHOLDI et al. 2008; BLIEK et al. 2004; BRUCE 
et al. 2008; YAMAZAWA et al. 2008). 
  
In this study, we show that 2 of 19 (10%) BWS patients with apparently 
sporadic BWS, actually display a deletion within ICR1. Long range PCR 
allowed us to identify a 1.8 kb deletion in one patient (KL41) similar to a 
deletion described in an unrelated familial case (SPARAGO et al. 2004) 
(SPARAGO et al. 2007) (Fig. 12). Additional primers were designed for 
the ICR1 domain and cloned fragments were bi-directionally sequenced 
to specifically characterize the 1.8 kb deletion. Another patient 
displayed a very small deletion involving only 8 bp in the B3 domain, 
116 bases 3‟ of CTCF binding site 4 (Fig. 13). Sandovici et al. 
(SANDOVICI et al. 2006) showed that there is an excess of hot-spots of 
recombination at imprinted loci, particularly at the 11p15 region, 
compared to the rest of the genome. This higher rate of recombination 
might explain the incidence and localization of deletions at ICR1. 
Parental analysis for the two patients with a deletion showed that both 
deletions were maternally inherited.  
 
The wild-type ICR1 domain is arranged in two repeat blocks and 
contains seven CTCF target sites. It has remained controversial 
whether the ICR1 deletion was sufficient to result in gain of DNA 
methylation (PRAWITT et al. 2005; RICCIO 2008). Previously described 
imprinting centre mutations that cause ICR1 gain of methylation are 
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deletions that delete 1.4–1.8 kb at the core of ICR1, fusing the two 
repeat blocks and abolishing one or two CTCF target sites (SPARAGO et 
al. 2004; SPARAGO et al. 2007). Intriguingly, another deletion, 
measuring 2.2 kb, abolishing three CTCF target sites while maintaining 
one repeat block, did not result in ICR1 gain of methylation (PRAWITT et 
al. 2005). It was suggested at the time that alteration of spacing rather 
than loss of CTCF target sites might be essential for ICR1 gain of 
methylation (PRAWITT et al. 2005). More recently, a larger deletion of 
5.3 kb removing both repeat blocks and six of the seven CTCF binding 
sites was shown to also result in gain of methylation at the seventh 
CTCF binding site (SCOTT et al. 2008). Surprisingly, an insertion of 2.9 
kb adding two CTCF binding sites between the two ICR1 repeat blocks 
was also shown to result in gain of methylation despite no loss of CTCF 
target sites or disturbance of the architecture within each block (SCOTT 
et al. 2008). 
 
In order to investigate the consequences of the deletions in our patients 
with the deletions (in particular the small 8 bp deletion) on the DNA 
methylation status at ICR1, bisulfite sequencing for CTCF binding sites 
and their flanking regions has been performed. Bisulfite sequencing of 
DNA allowed us to precisely analyze each CpG dinucleotides at CTCF 
binding sites and their flanking regions.  
 
In BWS KL41 case, the deletion (1.8 kb) that abolished CTCF binding 
sites 2 and 3, resulted in a gain of methylation at CTCF binding sites 1, 
4 and 6-7 (methylation indexes were more than 70%) (Fig. 16b). In the 
8 bp deletion case, the gain of DNA methylation was nearly complete in 
tongue tissue and the extent of gain of methylation was homogenous 
with methylation indexes in the same range at the various CTCF 
binding sites (Fig. 17). The deletion did not remove any of CTCF 
binding sites.  Although, this deletion was very small and did not alter 
the structure of the ICR1 (in terms of number of repeated sequences 
and the spacing of CTCF binding sites), it resulted in a gain of 
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methylation at ICR1. Thus, the small 8 bp deletion described here does 
not really support a CTCF binding sites spacing hypothesis.  
 
In the previous reports, ICR1 gain of methylation associated with 
insertion or deletion had a mosaic pattern and affected only a 
proportion of mutated cells (CERRATO et al. 2008; SCOTT et al. 2008; 
SPARAGO et al. 2007). In this study, our data are a little different with a 
nearly complete gain of methylation at all CTCF binding sites in the two 
patients with a deletion.   
 
Previous reports have also shown that the level of methylation in 
patients with ICR1 deletions is different between the proximal (B7-A2) 
and distal (B4-A1) CTCF binding sites (CERRATO et al. 2008; SPARAGO 
et al. 2007). In our study, we showed that the level of methylation is 
similar at all CTCF binding sites.  
 
No abnormality at ICR1 or the CTCF gene has been found in the 
familial cases (Fig. 15). This family is very special in the way that three 
brothers displayed an overgrowth phenotype when two sisters were 
unaffected. This familial pedigree was evocative of an X linked 
disorder. As there is an X linked overgrowth disorder that shares some 
phenotypes with BWS, this family was initially investigated for the X 
linked Simpson-Golabi-Behmel syndrome (PILIA et al. 1996). The 
sequencing of the Glypican 3 gene was normal. Instead, analysis of the 
11p15 region showed that the affected brothers displayed a gain of 
methylation at ICR1. The father who was born with macrosomia and 
displays a supernumerary nipple had a normal methylation profile. At 
this stage the mechanism of the methylation defect in this family 
remains unknown. 
 
In order to identify the cause of the epigenetic defect in the SRS 
patients with loss of methylation at ICR1, a long range PCR of ICR1 
and direct sequencing of the CTCF binding sites and their flanking 
region have been conducted. No deletions have been found in SRS 
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cases. However, a single nucleotide variation was found in a non 
familial SRS case (Fig. 14). This heterozygous variation was outside of 
CTCF binding sequences, 3‟ of CTCF binding site 7. This single 
nucleotide variation is not a known SNP and was not found in 50 
control samples. Bisulfite sequencing showed a loss of methylation at 
CTCF binding sites. A SNP within the 4th CTCF binding site allowed us 
to confirm that there was a loss of methylation on the paternal allele 
(Fig. 18). At this stage, we can not be sure if this loss of methylation 
results from the mutation or if the loss of methylation results from 
another unknown mechanism like in most SRS patients. Unfortunately, 
no cells or tissues are available for this patient to test, by chromatin 
immunoprecipitation or chromosome conformation capture, the 
relevance of the mutation. 
 
The sequence of the CTCF gene was normal for all BWS patients 
including the familial cases. Mutations of the CTCF gene have been 
previously described in several tumors including two Wilms‟ tumors 
(FILIPPOVA et al. 2002). Wilms' tumor is very common in BWS patients, 
and more particularly in BWS with a gain of methylation at ICR1 
(ENKLAAR et al. 2006). However, other studies failed to find any CTCF 
mutation in Wilms‟ tumors (CUI et al. 2001; YEH et al. 2002). Regarding 
the role of CTCF in the maintenance of the hypomethylated state of the 
maternal allele, we hypothesized that deleterious mutation of CTCF 
might account for some BWS with ICR1 gain of methylation. No 
mutation was found and our data are consistent with a previous 
publication (CERRATO et al. 2008). 
 
The ICR1 11p15 region is genetically highly variable and displays a lot 
of SNPs. When we sequenced this region in our cohort of patients, we 
described new genetic changes (2 SNPs) that were not found in more 
than one patient and were not documented as polymorphisms. We 
evaluated precisely the frequency of the two new SNPs in the normal 
population (positions 5269 and 7648 according to the reference 
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sequence AF 125183) and we also documented the frequency of other 
previously described SNPs (table VIII). 
 
In conclusion, we described two new BWS cases and one SRS case 
with ICR1 genetic defect. We show that a very small 8 bp deletion 
which does not delete any of the CTCF binding sites results in a gain at 
methylation of all CTCF binding sites. Although accounting for a very 
small proportion of BWS patients, these deletions should be 
recognized. BWS patients with ICR1 gain of methylation have a high 
risk of tumors (mainly Wilms‟ tumors) and their molecular diagnosis and 
the recognition of a deletion is particularly important for genetic 
counseling and tumor surveillance.  
 
At this stage, the mechanism of the methylation defect at ICR1 remains 
largely unknown in both BWS and SRS patients. By opposition to BWS 
patients with ICR2 loss of methylation, gain of DNA methylation is 
localized to the H19/IGF2 ICR1 domain and does not affect other 
paternally- or maternally methylated loci (BLIEK et al. 2008). Recent 
studies have demonstrated that other cofactors such as cohesin 
(WENDT et al. 2008), MBD3 (REESE et al. 2007), the EZH2 histone 
methyltransferase (LI et al. 2008) or 91H, a 120 kb H19 antisense RNA 
(BERTEAUX et al. 2008) participate to the regulation of imprinting and 
chromatin looping at the H19/IGF2 ICR1 domain but their putative role 
in imprinting disorders have not been addressed yet. Alternatively, 
other recent studies suggest that particular genotypes at 11p15 might 
affect the susceptibility to epigenetic signals (HEIJMANS et al. 2007) and 
extensive future studies should also address this question. 
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